PTC Inc. (PTC)
PTC to Report Q1 Earnings: Here's What Investors Should Know
PTC's fiscal first-quarter performance is likely to have been driven by demand for PLM and CAD in a tough selling environment and go-to-market realignment.
PTC Faces Markets And Sales Motion Uncertainties (Downgrade)
PTC reported better-than-expected FQ4 2024 results, but faces challenges in top line revenue growth due to macro headwinds and go-to-market changes. The global PLM market is projected to grow at a 9.2% CAGR through 2030, driven by cloud-based systems and smart product demand. PTC's financials show improved operating income and gross margins, but international revenue growth is lagging, particularly in Europe.
This Software Stock Could Be the Best Investment of the Decade
Every consumer knows about the growing role of artificial intelligence (AI) and wirelessly enabled digital technologies in our daily lives. But not everyone knows about the seismic shift these developments are having on the manufacturing industry and the role that an industrial software company like PTC (PTC 0.24%) is playing in it.
Why Is PTC Inc. (PTC) Up 5.7% Since Last Earnings Report?
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
PTC, Microsoft & Volkswagen Collaborate on Codebeamer AI Copilot
PTC partners with MSFT and Volkswagen for a Codebeamer AI Copilot designed to simplify product development.
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics (PTCT) soared 16% Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis (NVS).
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecules.
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis
PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological disorder.
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
On Tuesday, PTC Therapeutics Inc PTCT revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients.
PTC Therapeutics discontinues development of ALS drug after trial failure
PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it did not meet the main goal in a mid-stage trial.
A Few Years From Now, You'll Wish You'd Bought This Undervalued Stock
A Few Years From Now, You'll Wish You'd Bought This Undervalued Stock
